Antibody drug conjugates market to be worth more than 15 billion in 2030, By Roots Analysis

Author : kevin987
Publish Date : 2021-03-24 05:22:27

Antibody drug conjugates market to be worth more than 15 billion in 2030, By Roots Analysis

Antibody drug conjugates (ADCs) represent a transformative approach to modern cancer treatment; over the years, this upcoming class of targeted therapeutic agents has generated significant enthusiasm within the medical science community


Roots Analysis is pleased to announce the publication of its recent study, titled, “Antibody Drug Conjugates Market (5th Edition), 2019-2030.”


The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapeutics over the next decade. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes:

  • A detailed assessment of the current market landscape of ADCs.
  • Elaborate profiles of the clinical stage companies (shortlisted based on phase of development of the lead drug) and their respective product portfolios.
  • An analysis of the most commonly targeted therapeutic indications and details of ADC candidates being developed against them, highlighting key epidemiological facts about the diseases and currently available treatment options, other than ADCs.
  • A list of key opinion leaders (KOLs) within this domain.
  • An insightful competitiveness analysis of biological targets.
  • An analysis of the partnerships that have been established in the recent past.
  • An analysis of the investments made.
  • A study of the various grants that have been awarded to research institutes engaged in projects related to ADCs, between 2011 and 2019 (till April).
  • An elaborate discussion on the various strategies that can be adopted by the drug developers across key commercialization stages, namely prior to product launch, during / post launch.
  • An analysis of the key promotional strategies that have been adopted by the developers of marketed products.
  • An assessment of the various therapeutics that are being evaluated in combination with ADCs.
  • A review of the evolution of ADC conjugation technologies.
  • An overview of the studies conducted to better analyze non-clinical data and support first-in-human (FIH) dose selection in ADCs.
  • An elaborate discussion on various factors that form the basis for the pricing of ADC products.
  • A case study on manufacturing of ADCs, highlighting the key challenges, and a list of contract service providers that are involved in this domain.
  • A case study on companies offering companion diagnostics.
  • A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
  • Eminent representatives from different biopharmaceutical companies confirm the sustained interest in ADC therapeutics, highlighting the technological innovation that is driving contemporary R&D initiatives
  • Presently, over 240 ADC therapy candidates are being evaluated in clinical / preclinical stages for treating a variety of solid tumors / hematologic cancers
  • The pipeline features product candidates that target a wide range of biological antigens and are equipped with different cytotoxic warheads; a number of companies are focused on developing novel drug conjugates
  • In order to gain a competitive edge in the market, ADC developers are actively exploring new biological targets, conducting clinical trials across different geographies to treat diverse disease indications
  • A number of eminent scientists from renowned universities, owing to their involvement in clinical development efforts, have emerged as key opinion leaders within this market
  • Over the years, more than 16,000 patents related to ADCs have been filed / granted across the world, indicative of the ongoing pace of R&D activity in this field of research
  • Several investors, having realized the opportunity within this upcoming segment of targeted cancer therapeutics industry, have invested over USD 5 billion, in the period between 2011 and 2019
  • The increasing interest in this field is also reflected in the partnership activity; deals inked in the recent past were mostly focused on licensing of products / technologies, involving both international and indigenous stakeholders
  • Type of payload
  • MMAE
  • DM4
  • Camptothecin
  • AM1
  • MMAF
  • Type of linker
  • VC
  • Sulfo-SPDB
  • SMCC
  • VA
  • Hydrazone linker
  • Others
  • Target Indications
  • Breast Cancer
  • Lymphoma
  • Leukemia
  • Urothelial cancer
  • Lung cancer
  • Ovaria cancer
  • Others
  • Target Antigen
  • CD30
  • HER2
  • CD22
  • CD33
  • Others
  • Small Molecule
  • Technology Providers
  • Seattle Genetics
  • ImmunoGen
  • StemCentRx
  • Immunomedics
  • Others
  • Key Geographies
  • North America
  • Europe
  • Asia Pacific


Transcripts of interviews held with the following senior level representatives of stakeholder companies:

  • Alan Burnett (Professor, School of Medicine, Cardiff University)
  • Aldo Braca (President and Chief Executive Officer) and Giorgio Salciarini (Technical Business Development Senior Manager, BSP Pharmaceuticals)
  • Anthony DeBoer (Director, Business Development, Synaffix)
  • Christian Bailly (Director of CDMO, Pierre Fabre)
  • Christian Rohlff, (Chief Executive Officer and Founder, Oxford BioTherapeutics)
  • Denis Angioletti (Chief Commercial Officer, Cerbios-Pharma)
  • John Burt (Chief Executive Officer, Abzena)
  • Jennifer L. Mitcham (Director, SMARTag ADCs and Bioconjugates) and Stacy McDonald (Group Product Manager, Catalent Pharma Solutions)
  • Laurent Ducry (Head of Bioconjugates Commercial Development, Lonza)
  • Mark Wright (Site Head, Piramal Healthcare)
  • Sasha Koniev (Chief Executive Officer & Co-Founder, Syndivia)
  • Tatsuya Okuzumi (Associate General Manager, Ajinomoto Bio-Pharma Services)
  • Toshimitsu Uenaka (Executive Director) and Takashi Owa (Chief Innovation Officer, Eisai)
  • Wouter Verhoeven (Chief Business Officer, NBE-Therapeutics)


Key companies covered in the report

  • Bristol Myers Squibb
  • AbbVie
  • Astellas Pharma
  • AstraZeneca
  • Daiichi Sankyo
  • Pfizer
  • Roche / Genentech
  • Synthon
  • Bayer HealthCare
  • Biotest Pharmaceuticals


For more information please click on the following link:


Other Offerings

  1. ADC Contract Manufacturing Market (3rd Edition), 2018-2030
  2. Gene Therapy Market (3rd Edition), 2019 - 2030
  3. Global T-Cell (CAR-T, TCR, and TIL) Therapy Market (4th Edition), 2019 – 2030


About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]


Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

[email protected]

Category : general

Get Help for Plain Basis under Experienced Experts and Go for your IT Exam with DA-100 Dumps

Get Help for Plain Basis under Experienced Experts and Go for your IT Exam with DA-100 Dumps

- A-100 Dumps, Microsoft DA-100 Questions Answers, Data Analyst Associate Exam Dumps PDF, Practice Questions, DA-100 Braindumps, DA-100 Study Material

England, Wales set for gay marriages in 2014 startling

England, Wales set for gay marriages in 2014 startling

- A bill to allow same-sex marriage in England and Wales is now law, though the unions arent expected

5 Top Breathtaking Scuba Diving Sites To Reveal Your Holidays

5 Top Breathtaking Scuba Diving Sites To Reveal Your Holidays

- plunging, you could swim close by fish and be imagining like youre one among them. By plunging, you may see the entire worldwide of submerged.

New Updated CompTIA N10-007 Dumps 2021

New Updated CompTIA N10-007 Dumps 2021

- Are you preparing for CompTIA N10-007 certification exam? Is your desire to clear the N10-007 exam in your first attempt to add a new feather to your cap?